Category: Health and wellness

Download PDF Brochure:

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=175119477

Browse in-depth TOC on ‘Healthcare Adhesive Tapes Market’
93 – Tables
43 – Figures
155 – Pages

View detailed Table of Content here:

https://www.marketsandmarkets.com/Market-Reports/healthcare-adhesive-tape-market-175119477.html

Acrylic is estimated to be the largest resin segment in the healthcare adhesive tapes market during the forecast period.

The acrylic segment is expected to account for the largest market share during the forecast period because of its better adhesion properties to a variety of substrates. Acrylic adhesive tapes are designed with high or low tack and high or low peel strength. These tapes are permeable to moisture that is measured by the moisture vapor transmission rate (MVTR). Acrylic healthcare adhesive tapes release off from body or skin without leaving adhesive residue. These tapes are preferred for stick-to-skin application because of the breathable nature compared to rubber adhesive tapes.

Request Sample Pages:

https://www.marketsandmarkets.com/requestsampleNew.asp?id=175119477

Fabric to account the largest share as a backing material in the healthcare adhesive tapes market during the forecast period.

The fabric is the most popular backing material used in the manufacturing of healthcare adhesive tapes. Fabric healthcare adhesive tapes are high in demand as they have high strength, toughness, good abrasion, and heat resistance, low creep at elevated temperatures, good chemical resistance, and excellent dimensional stability. Owing to its strength, these tapes are used for securing dressings, catheters, tubing, and wound dressing and for other medical purposes.

North America to account for the largest share of the healthcare adhesive tapes market during the forecast period.

Various factors have contributed to the growth of the North American healthcare adhesive tapes market. These factors include the rising incidence of chronic wounds, increase in the number of elderly citizens, increasing patient awareness on wound care, aging population, and technological advancements in the healthcare industry. The surgical adhesive tapes application has witnessed steady growth along with an increase in orthopedic and trauma, neurosurgery, cardiovascular, and gastroenterology. The increasing number of orthopedic procedures in the US is driving the demand for bandages and healthcare adhesive tapes.

Major vendors in the Healthcare Adhesive Tapes Market include 3M (US), Cardinal Health, Inc. (US), Nitto Denko Corporation (Japan), Johnson & Johnson Services, Inc. (US), PAUL HARTMANN AG (Germany), Avery Dennison Corporation (US), NICHIBAN Co., Ltd. (Japan), Smith & Nephew (UK), Lohmann GmbH & Co.KG (Germany), Scapa Group Plc (US), Medline Industries Inc. (US), and Essity Aktiebolag (PUBL) (Sweden).

Get 10% Free Customization on this Report:

https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=175119477

Browse Adjacent Markets: Coatings Adhesives Sealants and Elastomers Market Research Reports & Consulting

Related Reports:

Medical Adhesive Tapes Market by Type (Acrylic, Silicone, Rubber), Backing Material (Paper, Fabric, Plastic), Application (Surgeries, Wound Dressings, Secure IV Lines, Splints, Ostomy Seals) – Global Forecast to 2022

Adhesive Tapes Market by Resin Type (Acrylic, rubber, silicone), Technology (Solvent, Water and Hot-Melt-Based), Substrate (PP, Paper, PVC), Application (Packaging, Healthcare, Electrical & Electronics, Automotive), and Region-Global Forecast to 2022

About MarketsandMarkets™ 

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies” revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the ‘Growth Engagement Model – GEM’. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write ‘Attack, avoid and defend’ strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets”s flagship competitive intelligence and market research platform, ‘Knowledge Store’ connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com 

Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg

CHICAGO, April 23, 2019 /PRNewswire/ — According to the new market research report Healthcare Adhesive Tapes Market by Resin (Acrylic, Rubber, Silicone), Backing Material (Paper, Fabric, Plastic), Application (Surgery, Hygiene, Wound Dressing, Secure Iv Lines, Ostomy Seal, Splint, Bandages, Diagnostic), and Region – Forecast to 2023′, published by MarketsandMarkets™, the Healthcare Adhesive Tapes Market is projected to grow from USD 27.2 billion in 2018 to USD 37.3 billion by 2023, at a CAGR of 6.51% during the forecast period. The major factor driving the healthcare adhesive tapes market includes the increase in demand for surgeries, wound dressings, hygiene, transdermal drug delivery, and many others, owing to their advantages in many medical applications. These adhesive tapes have wide acceptability due to factors such as low cost and easy availability, as compared to traditional medical procedures.

Read Full Article

This collaboration is expected to take several forms, including joint design and implementation of clinical research, working meetings at scientific conferences like the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), and IDWeek, cross-entity working groups with diverse functional group participation, clinical trial innovations, data and protocol exchanges, and, contractual, regulatory, and systems harmonization.

‘We at the ARLG have long admired the work being done by COMBACTE to increase the efficacy of antimicrobial drug development,’ said Vance Fowler, MD, an investigator at the DCRI and co-principal investigator of the ARLG. ‘Combining our efforts will allow us to maximize the work we both do to stop the advancement of antibacterial resistance.’

Both organizations have been working toward the same mission since each launched in 2013, and now, the two groups will share their work to increase synergy and avoid duplicative efforts in clinical research.

‘We have already made efforts to expand our reach across Europe, where an increasing number of people suffer from infections caused by antibiotic-resistant bacteria,’ said Marc Bonten, MD, coordinator of COMBACTE and a professor at UMC Utrecht. ‘But by collaborating and sharing our progress with the ARLG, we can make a truly global impact beyond this population — an important consideration in a globally connected era in which epidemics travel across oceans quickly.’

As part of the agreement, the ARLG will have the opportunity to lead and coordinate U.S.-based studies for all clinical research initiated by COMBACTE, while COMBACTE will have the opportunity to lead and coordinate ARLG-initiated projects in Europe.

Earlier this year the European Clinical Research Alliance on Infectious Diseases (ECRAID) was formed, merging COMBACTE”s more than 850 clinical trial sites and 650 laboratories with the network of primary care sites coordinated by The Platform for European Preparedness Against (Re-)Emerging Epidemics (PREPARE) to form a European-wide sustainable clinical research organization for infectious diseases and antimicrobial resistance. The ARLG, with established collaborations in 19 countries, will help to expand these efforts outside of Europe. The alliance will enable innovative, flexible, and adaptive collaboration between the DCRI and UMC Utrecht.

‘This is an exciting year for PREPARE to expand its work in reducing a serious public health threat,’ said Herman Goossens, MD, coordinator of PREPARE and professor at University of Antwerp and UMC Utrecht. ‘First, we joined forces with COMBACTE by forming ECRAID, and now, we welcome a partnership with the ARLG, which will help all three organizations leverage a wider set of resources and a deeper pool of expertise.’

The ARLG is supported by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, under Award Number UM1AI104681. COMBACTE-NET, COMBACTE-CARE, and COMBACTE-MAGNET receive support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115523 | 115620 | 115737 resources of which are composed of financial contribution from the European Union Seventh Framework Programme (FP7/2007-2013) and EFPIA companies in kind contribution. COMBACTE-CDI receives support from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement n° 777362 resources of which are composed of financial contribution from the European Union”s Horizon 2020 research and innovation programme, and EFPIA. PREPARE is funded by the European Union”s FP7 Programme n° 602525. ECRAID is funded by the European Union”s Horizon 2020 Programme n° 825715.

About the Antibacterial Resistance Leadership Group (ARLG)

The Antibacterial Resistance Leadership Group (ARLG) consists of more than 50 leading experts working together to combat the antibacterial resistance crisis and improve patient care. It accomplishes this goal through a scientific agenda that prioritizes areas of unmet needs, innovates clinical trial design, and informs practice-changing guidelines. Created in 2013, the ARLG receives its funding from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. It is facilitated by the Duke Clinical Research Institute and works under the thought leadership of an executive committee and two principal investigators: Vance Fowler, MD, of Duke University, and Henry ‘Chip’ Chambers, MD, of University of California, San Francisco.

About COMBACTE

In November 2011, the European Commission, as part of its action plan to combat the increasing threat of antimicrobial resistance, called for ‘unprecedented collaborative research and development effort to bring new antibiotics to patients,’ including the launch of the sixth, the eight and the eleventh IMI Calls for Proposals in May 2012, December 2012 and December 2013 respectively, as part of the program entitled ‘New Drugs 4 Bad Bugs (ND4BB).’ Within the ND4BB program are the COMBACTE-NET, COMBACTE-MAGNET, COMBACTE-CARE, and COMBACTE-CDI consortia, which were formed in January 2013 January, March 2015, and November 2017, respectively. The COMBACTE program management office is based in the University Medical Center Utrecht, one of the largest public health institutions in the Netherlands.

Media contact

Eric Trinthamer, UMC Utrecht
Phone: +31 6 21 55 66 58
Email: h.j.e.trinthamer@umcutrecht.nl

Mark Slagle, ARLG
Phone: +1 919-668-8031
Email: mark.slagle@duke.edu

UTRECHT, Netherlands and DURHAM, N.C., April 13, 2019 /PRNewswire/ — The U.S.-based Antibacterial Resistance Leadership Group (ARLG), part of the Duke Clinical Research Institute (DCRI) and the University Medical Center (UMC) Utrecht, the managing entity of the COMBACTE (Combatting Bacterial Resistance in Europe) consortium, will work together to solidify a comprehensive global community to combat the threat of antibiotic resistance around the world.

[[[tasteofexc

Read Full Article

Rise in the adoption of companion animals and the growing prevalence of animal diseases propel the growth of the global animal vaccines market

Surge in prevalence of animal diseases, growth in ownership of companion animal, rise in demand for pet insurance, and increase in animal health expenditure drive the growth of the global animal vaccines market. However, highly competitive meat & milk prices and unfavorable impact of veterinary vaccines on animal & human health hamper market growth. Nonetheless, rapid advancement in vaccine products and increased demand for hybrid animals worldwide is set to would provide lucrative opportunities to emerging market players in the near future.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/1988 

DNA vaccines segment to encounter the fastest growth rate through 2025

By product type, the DNA vaccines segment is projected to grow at the highest CAGR of 7.8% during the forecast period, owing to their cost-effective nature, easy development and production, negligible risk of infection, and long term persistence of immunogenicity. However, the attenuated vaccines segment is expected to continue its dominance and occupy one-third of the global market share by 2025, due to their ability to provide stronger immunity as compared to other vaccines and reducing the need for booster vaccines later on.

Cattle segment to dominate the global market in the near future

By animal type, the cattle segment is anticipated to generate more than one-third of the global revenue by 2025, on account of increased meat & milk consumption and surge in demand for dairy products. However, the companion animal segment is expected to be the fastest growing segment from 2017 to 2025, with a CAGR of 6.4%, due to an increase in their adoption rate and rise in awareness regarding the importance of vaccines for dogs and cats.

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/1988 

North America to contribute the largest revenue throughout the forecast period

North America occupied almost one-third of global market revenue in 2017 and is expected to continue its dominance through 2025. The region has a high adoption rate of companion animals and has witnessed a surge in meat & milk consumption. However, Asia-Pacific is projected to register the highest CAGR of 6.5% during the forecast period, due to the rise in pet ownership and increased incidence of various zoonotic diseases.

Key market players

The key players analyzed in the report include Merck & Co., Inc., Zoetis Inc., Ceva Sant Animale, Sanofi S.A., Romvac, Vaxxinova, Biovac, Merial, and Anicon Labor GmbH. They have adopted different strategies including collaborations, joint ventures, partnerships, expansions, mergers & acquisitions, and others to gain a strong position in the industry.

Access KNOWLEDGE TREE (Premium on-demand, subscription-based pricing model) at: https://www.alliedmarketresearch.com/knowledgetree

Knowledge tree is a cloud-based intelligence platform that offers more than 2,000 selective, off-the-shelf reports on niche markets to enable our clients gain deep insights on the latest trends, dynamic technologies, and emerging application areas.

Similar Reports:

Veterinary Point of Care Blood Gas Analyzers Market – Global Opportunity Analysis and Industry Forecast, 2017-2023

Animal Therapeutics and Diagnostics Market – Global Opportunity Analysis and Industry Forecast, 2014-2022

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of ‘Market Research Reports’ and ‘Business Intelligence Solutions.’ AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com

Web: https://www.alliedmarketresearch.com

Logo: https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg  

PORTLAND, Oregon, April 9, 2019 /PRNewswire/ — Allied Market Research recently published a report, titled, Animal Vaccines Market by Product Type (Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Conjugate Vaccines, Recombinant Vaccines, and DNA Vaccines) and Animal Type (Companion animals, Cattle, Fish, Pigs, Poultry, and Sheep]: Global Opportunity Analysis and Industry Forecast, 2018 – 2025′. According to the report, the global animal vaccines market generated $8.1 billion in 2017 and is expected to garner $12.8 billion by 2025, growing at a CAGR of 5.9% during the forecast period, 2018-2025.

[[[tasteofexc

Read Full Article

Among three types of tests performed in the global HIV/AIDS diagnostics market, the rapid test (POC) segment showcases maximum market share. This is because of the rising popularity of the test owing to its swift results and easy usage. Region-wise, North America is a remarkable shareholder in the global HIV/AIDS diagnostics market. This is attributed to the growing awareness regarding different diagnosis and advanced research and development facilities in the region.

Get PDF Brochure for Research Insights at https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=26582

Rising Governments” Initiatives in Reducing AIDS Boosts HIV/AIDS Diagnostics Market

Various diagnosis tests are required for detecting the existence of the HIV virus. The AIDS/HIV diagnosis can be performed by saliva test, blood test, and viral load test. The most effective and efficient test results are acquired by ELISA test and Western Bloat Method. The growth of the global HIV/AIDS diagnostics market is fueled by the rising prevalence of AIDS worldwide and several governmental initiatives to promote the awareness about HIV/AIDS.

Furthermore, the people from the region of lower literacy rate are not aware of changing lifestyle, transmission mode of blood, and safety during sex. Such factors lead to the raised number of HIV cases. Hence, governments of various countries along with NGOs are taking approach to improve HIV diagnostics and making the diagnostics procedures easily available and accessible to the general people. Such factors are also propelling expansion in the global HIV/AIDS diagnostics market.

Request a Sample of Report at https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=26582

HIV Rapid Diagnostics Test Important to Obtain Early Results

Various countries worldwide are adopting a strategic combination of HIV testing service models on the basis of the nature of context, epidemic, available resources, and cost-effectiveness. Such combination facilitates the HIV diagnosis as soon as possible for curing the disease on time. Thus, governments of several countries have launched HIV rapid diagnostics test kits for immediate return of results and initiating treatments rapidly. Such inventions are also booting the global HIV/AIDS diagnostics market.

Request For Discount On This Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=26582

Transparency Market Research (TMR) records that the global HIV/AIDS diagnostics market is witnessing a moderate level of competition. This is due to the active participation of a handful of uppermost players, who are competing against one another. However, the competition is mild also on account of a small number of products which were being approved for commercial use. The level of competition existing between potential players is likely to escalate as they are adopting various competitive pricing strategies.

Another influencing factor behind keeping the competition moderate includes high entry barriers to new aspiring players. This is because of the intense research required for developing diagnostic kits, which could be quite hectic for beginners. Moreover, until now, most of the products launched in the U.S were only used for research purposes. The dominant players in the HIV/AIDS diagnostics market are acquiring several key tactics to stay abreast with the latest trends in the market for successfully carrying out their research.

Request For Custom Research – https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=26582

Various uppermost and startup firms in the global HIV/AIDS diagnostics market are concentrating on capacity expansion through mergers and acquisitions. They are also focusing on channelizing efforts for offering cost-effective diagnostics for HIV/AIDS. On the other hand, a few vendors in the market have made impressive strides through investing in research and development and innovation or introduction of new products. Some active companies operating in the global HIV/AIDS diagnostics market are OraSure Technologies, Dickinson and Company, Becton, F. Hoffman-La Roche Ltd., and Abbott Laboratories.

Browse Press Release – https://www.transparencymarketresearch.com/pressrelease/hiv-aids-diagnostics-market.htm

The review is based on a market research report by TMR, titled, ‘HIV/AIDS Diagnostics Market (Product – Kits and Reagents and Instruments; Test Type – Rapid Tests (POC), ELISA, and Nucleic Acid Tests; End User – Hospitals, Private Diagnostic Laboratories, and Academic and Research Institutes) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 – 2025′.

Popular Research Reports by TMR:

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company”s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR”s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR”s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact

Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY – 12207
United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
Research Blog: https://theglobalhealthnews.com/

Logo: https://mma.prnewswire.com/media/664869/Transparency_Market_Research_Logo.jpg

ALBANY, New York, April 9, 2019 /PRNewswire/ — According to experts from TMR, the global HIV/AIDS diagnostics market was valued at US$2.606 bn in 2016. The HIV/AIDS diagnostics market to become worth US$5.74 bn by 2025 end. Experts project this growth to occur at an impressive CAGR of 9.3% during the forecast period from 2016 to 2025.

[[[tasteofexc

Read Full Article

Hannah Deacon, a tireless campaigner for access to medical cannabis in the UK, led a high-profile campaign on behalf of her young son Alfie Dingley which helped change the law last year. Alfie was the first person in the UK to receive a permanent medical cannabis license, obtained by Professor Mike Barnes, ECH”s Chief Medical Officer.

Seven-year-old Alfie Dingley suffered up to 500 life-threatening seizures a month, and was admitted to hospital 48 times a year as a result of his severe epilepsy. Following successful treatment with cannabis oil, he has had only one hospital admission in a year, his seizures are controlled, and he can now live a more normal life. Although around 500,000 people in the UK have epilepsy, only one other person has been prescribed the treatment on the NHS[i].

ECH is committed to building the infrastructure that will make medical cannabis more readily acceptable and accessible, by delivering clinical education, access to consultation and treatment for people living with a range of chronic and debilitating conditions.

As ECH Patient Advocacy Specialist, Hannah will support the teams behind ECH, the network of Medical Cannabis clinics and The Academy, an online educational platform, to support the safe and effective use of medical cannabis. She will advise on the specific needs of patients who are navigating the system since the Home Office decision in November, and are still struggling to access medical cannabis. She will also help to ensure ECH”s innovation in medical cannabis treatment best reflects the needs of patients with high unmet needs, including those living with chronic pain, neurological and psychiatric conditions.

Hannah Deacon commented: ‘Families were delighted when the law changed last year, they thought their battle was over. Now they are in despair. The families I speak to every day have exhausted all their options, and are suffering terribly but they still can”t access the medical cannabis that could help them like it has helped Alfie.

I”m delighted to join ECH to continue to fight the battle to overcome barriers to medical cannabis in the UK, support better education and ensure patients right across the country get the access they need and the help they deserve.’

Stephen Murphy, ECH Group Managing Director, added: ‘The legalisation of prescription cannabis has given people with chronic illnesses hope, and it is ECH”s mission to fulfil that. We are thrilled that Hannah Deacon, who understands what it means to fight for the care her son deserves, has come onboard to share her insight and counsel on what more we can do to make sure that other patients – like Alfie – are no longer denied the treatment they need to survive.’

ABOUT ECH

ECH is at the forefront of transforming the medical cannabis industry to improve treatment options for patients with chronic and debilitating conditions. Supported by a team of world-leading medical advisors, our unrivalled group of companies take a comprehensive approach to improving access to medical cannabis for eligible patients by providing key infrastructure and educational services.

Committed to opening up the UK market to improve access to medical cannabis, ECH opened the first of a planned network of specialist medical cannabis clinics in March 2019. The Medical Cannabis Clinics are led by Clinical Director, Professor Michael Barnes, who also founded The Academy of Medical Cannabis, the only online education platform which seeks to improve responsible use of medical cannabis. Professor Barnes is the world”s foremost expert in medical cannabis whose 2016 report ”Cannabis: The Evidence for Medical Use” helped pave the way for legalisation of medical cannabis.

Our wider portfolio includes market intelligence firm Prohibition Partners, the foremost arena to share knowledge and shape the future of medical cannabis in Europe, Cannabis Europa and CBD brand group Amkeu. These holdings provide ECH with a fundamental anchor in the cannabis investment market, while helping it define this emerging industry.

[i] https://www.mirror.co.uk/news/uk-news/kids-forced-leave-uk-survive-14150885

Logo: https://mma.prnewswire.com/media/813128/ECH_Logo.jpg

 

 

LONDON, April 3, 2019 /PRNewswire/ — ECH, the group of companies behind the launch of the UK”s first medical cannabis clinic, has today reinforced its ambition to expand patient access by appointing Hannah Deacon as its Patient Advocacy Specialist.

[[[tasteofexc[[[tasteofexc

Read Full Article

NEW YORK, April 1, 2019 /PRNewswire/ — Cannabis has become one of the most controversial topics on many countries” political agendas. Cannabis is still internationally illegal under regulatory statutes, but clinical trials and research have led countries to explore opportunities within the medical cannabis market. However, the recreational market is still widely being heavily enforced. Nonetheless, certain regions have moved to decriminalize, or even fully legalize, recreational cannabis use. Unlike marijuana, hemp”s main component is CBD. While THC provides psychoactive effects to consumers, CBD does not induce psychoactive effects, but provide a therapeutic and relaxing effect akin to that of THC. Furthermore, because CBD does not provide any psychoactive effects, many countries have allowed personal use of the CBD as long as it contains less than 0.3% THC. According to data compiled by Hemp Business Journal, a division of New Frontier Data, the total sales for the U.S. hemp industry totaled USD 820 Million and is expected to grow to reach USD 1.9 Billion by 2022. Additionally, the market is projected to grow at a CAGR of 14.4% throughout the forecast period from 2018 to 2022. Overall, the industry is expected to be driven by increasing sales in the hemp-derived CBD and industrial application segments. Chineseinvestors.com Inc. (OTC: CIIX), Tilray, Inc. (NASDAQ: TLRY), Canopy Growth Corporation (NYSE: CGC) (TSX: WEED), Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON), Aphria Inc. (NYSE: APHA) (TSX: APHA)

In 2017, the hemp-derived CBD product segment delivered USD 190 Million in sales, accounting for 23% of the overall market. The hemp food segment, which delivered USD 137 Million in sales, accounted for 17% of the hemp market that same year. By 2022, the food segment is expected to reach USD 212 Million as the segment is seeing major investments, primarily by large beverage corporations looking to enter into the cannabis-infused beverage industry. Many are looking to use cannabidiol, or CBD, to create therapeutic non-alcoholic drinks for consumers. However, CBD still remains popular among consumers in forms of capsules, oils, and flower itself. While the beverage industry is growing rapidly, other forms of CBD-based products are also seeing large growth. ‘The fact that a consumer-cannabis product has captured the attention of so many folks—from customers on the street to executives in the boardroom—reveals something far more lasting than whatever may come from this beverage product, even if it never launches,’ said Ben Curren, Chief Executive Officer and Founder of Green Bits. ‘What it reveals is that now, you and I and millions of people can picture this: the substance that once was considered the nation”s most deadly, the very banner of America”s war on drugs, might someday soon be ‘Brought to You By Coke,’ and not just as a social lubricant but as a sports recovery product applicable to an even wider audience.’

Chineseinvestors.com Inc. (OTCQB: CIIX) just announced breaking CBD news this morning that, ‘that its wholly owned foreign enterprise , CBD Biotechnology Co. Ltd. (‘CBD Biotech’), will participate in the 29th Vietnam International Trade Fair (Vietnam Expo) at the Hanoi International Exhibition Center (ICE) being held on April 10-13, 2019 in Hanoi.

As a featured exhibitor at the Vietnam Expo, CBD Biotech will introduce the new concept of ‘hemp plant extracting’ and cosmetics.  CBD Biotech will exhibit its self-branded hemp-infused skincare line as well as its hemp wine.  CBD Biotech is one of the first companies to offer skincare products infused with hemp oil and hemp leaf extract in China. Focused on building new markets for industrial hemp products in throughout Asia, this expo will allow CBD Biotech to  explore possible partnership opportunities for the Vietnamese market.

‘The Vietnam Expo continues to be an important business destination to build bridges for trade promotion, foreign relations, facilitating commerce and attracting trade between Vietnamese and foreign enterprises,’ said Ms. Summer Yun, CEO of CBD Biotechnology Co. Ltd. ‘A pioneer in the Chinese market for hemp-infused skincare products and a Chinese originator of ‘hemp plant extracting’ in combination with skincare, CBD Biotech”s participation in this year”s Vietnam Expo will give our brand the exposure needed to become an influencer within the Asian market. We anticipate creating lucrative export opportunities and exploring possible expansion to more Southeast Asian countries and members of ASEAN.’

The Vietnam Expo, one of Vietnam”s largest, most influential international exhibitions,

is hosted by the Ministry of Industry and Trade of Vietnam. This year the event  will showcase 760 companies with over 1,000 international booths, with 35% of the companies being foreign and 65% Vietnam-based. The event provides foreign exhibitors the opportunity to educate Vietnamese business professionals regarding global trends and provides attendees the opportunity to purchase new products and learn about new technologies and investment opportunities.

CBD Biotech”s current line of skincare products features the Popular Series which includes hemp peptide concentrate liquid, aqua bio-magnetic mask and hemp hyaluronic acid, the Live Oxygen Series which includes oxygen cleansing foam, oxygenated water and live oxygen cream, the Plant Series which includes Huanyan tone-up cream, aqua double moisturizer and peptide mineral essence, and the New Products Series which includes hemp eye pads, horse oil soap and hemp eye cream.

About ChineseInvestors.com – Founded in 1999, ChineseInvestors.com endeavors to be an innovative company providing: (a) real-time market commentary, analysis, and educational related services in Chinese language character sets (traditional and simplified); (b) advertising and public relation related support services; and (c) retail, online and direct sales of hemp-based products and other health related products. For more information, visit ChineseInvestors.com.’

Tilray, Inc. (NASDAQ: TLRY) is a global pioneer in the research, cultivation, production and distribution of cannabis and cannabinoids currently serving tens of thousands of patients and consumers in twelve countries spanning five continents. Tilray, Inc. recently announced that it had entered into a definitive agreement, pursuant to which Tilray will acquire all of the issued and outstanding securities of FHF Holdings Ltd. from Compass Group Diversified Holdings, LLC (NYSE:CODI) and other shareholders of Manitoba Harvest. Under the terms of the Agreement, Tilray will acquire Manitoba Harvest on a cash and debt-free basis, for an aggregate purchase price, including cash and class 2 Common Stock in the capital of Tilray, of up to CAD 19 Million pending the achievement of certain milestones after the closing of the Transaction. Together, Tilray and Manitoba Harvest plan to grow both companies” revenue while bringing nutritious hemp foods and supplements to more households across the U.S. and Canada. The acquisition will expand Tilray”s product portfolio into the natural foods category and bring Manitoba Harvest expertise in working with cannabinoids, including cannabidiol (CBD). By leveraging Manitoba Harvest”s established distribution network, Tilray plans to accelerate its expansion into the U.S. and Canadian markets, where legal, for CBD products. Manitoba Harvest also brings to Tilray an experienced team and manufacturing capabilities, including the addition of two high quality BRC AA+ certified manufacturing facilities as well as significant sales and distribution capabilities. ‘Tilray”s acquisition of Manitoba Harvest is a milestone for the cannabis industry. It builds on the strategic partnerships we have formed with consumer brand industry leaders and demonstrates our track record of disrupting the global pharmaceutical, alcohol, CPG, and functional food and beverage categories,’ said Brendan Kennedy, Tilray President and Chief Executive Officer. ‘We”re excited to work with Manitoba Harvest to develop and distribute a diverse portfolio of branded hemp-derived CBD food and wellness products in the U.S. and Canada.’

Canopy Growth Corporation (NYSE: CGC) (TSX: WEED) is a world-leading diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms. Canopy Growth Corporation and Sequential Brands Group, Inc. (NASDAQ: SQBG) recently announced that Martha Stewart had joined the Company in an advisory role to assist with developing and positioning a broad new line of product offerings across multiple categories. With decades of success in publishing, broadcasting, online and merchandising, Martha Stewart has firmly cemented herself as one of the most well-respected businesswomen in the United States. Along with a deep understanding of what consumers in the United States and around the world want, Martha has been one of the most vocal advocates for animals, championing the health and wellness of pets and farm animals alike. With several clinical trials underway, Canopy Growth will be leaning on Martha”s vast knowledge of consumer products while exploring the effectiveness of CBD and other cannabinoids as they relate to improving the lives of both humans and animals. As previously reported in January 2019, Canopy Growth has developed diverse product offerings specific to hemp-derived CBD and the Company looks forward to working closely with Martha Stewart as they further develop and introduce these products to market in the future. Canopy Growth previously reported that it will invest between USD 100 Million and USD 150 Million in a hemp industrial park in New York State with an intended purpose of being the Company”s first hemp facility in the United States. ‘As soon as you hear the name Martha, you know exactly who we”re talking about,’ shared Canopy Growth Chairman and co-Chief Executive Officer , Bruce Linton. ‘Martha is one of a kind and I am so excited to be able to work alongside this icon to sharpen our CBD product offerings across categories from human to animal.’

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) is a globally diversified and vertically integrated cannabis company with a presence across four continents. Recently, Cronos Group Inc. and Ginkgo Bioworks Inc., the organism company, announced a landmark partnership to produce cultured cannabinoids. Using its platform technology for organism design and development, Ginkgo will complement Cronos Group”s technologies for producing a full spectrum of cannabinoids. As part of this unprecedented deal, Cronos Group has agreed to issue a specific number of common shares in tranches subject to Ginkgo”s achievement of certain production milestones. As two of the leading companies in their respective industries, Cronos Group and Ginkgo believe that they are best-suited to unlock the potential of innovation in the cannabis industry. Cronos Group brings a deep understanding of the plant”s biological structure and function, while Ginkgo brings 10 years of experience designing microorganisms for the production of cultured products across pharmaceuticals, agriculture, flavors, fragrances, and more. ‘Cronos Group is building the world”s most innovative cannabinoid platform,’ said Mike Gorenstein, Chief Executive Officer of Cronos Group. ‘The potential uses of cannabinoids are vast, but the key to successfully bringing cannabinoid-based products to market is in creating reliable, consistent, and scalable production of a full spectrum of cannabinoids, not just THC and CBD. We are thrilled to partner with Ginkgo; their biological engineering capabilities and disruptive technology platform are unrivaled. Together we can revolutionize the cannabis industry.’

Aphria Inc. (NYSE: APHA) (TSX: APHA) is a leading global cannabis company driven by an unrelenting commitment to our people, product quality and innovation. Aphria Inc. and Rapid Dose Therapeutics Inc. (CSE: DOSE) recently announced that they have expanded the scope of their previously announced agreement expanding the territory where Aphria has been granted exclusive preferred rights to license, manufacture, distribute and sell RDT”s QuickStrip™ innovative, proprietary delivery technology for the cannabis market to Germany. RDT”s proprietary QuickStrip™ technology is a Quick, Convenient, Precise, Discreet™ oral fast-dissolving drug delivery system that offers a smoke-free choice to consumers. Aphria expects to produce and distribute CBD-only Quickstrips™ in Germany by Spring 2019. As part of the Agreement, Aphria maintains the option to add future international markets as the opportunity in those markets evolve. ‘Germany is one of the most sought-after cannabis markets today, and Aphria continues to take a comprehensive approach to ensure a leading presence in the country as the opportunity evolves,’ said Jakob Ripshtein, President of Aphria. ‘Aphria is committed to bringing advanced products and innovations to cannabis markets around the world, and this agreement with RDT will enable us to bring QuickStrip™ technology to the German market and offer a unique nutraceutical product that delivers a consistent dosage.’

Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia

Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com  

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the ”Site”) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For Chineseinvestors.com Inc. financial and corporate news dissemination, FinancialBuzz.com expects to be compensated three thousand five hundred dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com.

Media Contact:
info@financialbuzz.com
+1-877-601-1879
Url: www.FinancialBuzz.com

FinancialBuzz.com News Commentary

[[[tasteofexc

Read Full Article

  • EQT invests in MHC Asia, a healthcare benefits administrator in Southeast Asia powered by a strong management team
  • MHC Asia aggregates health, wellness and lifestyle data to provide actionable insights that enable organizations to customize their health and wellness offerings with the aim to improve the quality of life of their employees and dependents and maintain an optimal balance between cost and quality of care  
  • EQT is partnering with the Founder and CEO, Dr Low Lee Yong and management to drive MHC”s next phase of growth

The EQT Mid Market Asia III Fund (‘EQT’) has today announced its investment in MHC Asia Holdings Pte. Ltd. (‘MHC’ or ‘the Company’). Founded in 1994, MHC is a leading healthcare benefits administrator in Southeast Asia, offering approximately 800,000 corporate patients access to panel of over 1,200 clinics and processing about 1.8 million medical claims annually.

Since its founding years, MHC has been striving to positively impact corporate managed healthcare in Singapore and surrounding regions. Equipped with strong artificial intelligence and analytical capabilities, MHC is able to identify trends early and intelligently optimize healthcare costs and quality of care. As such, MHC maximizes value creation for its business partners beyond the traditional third-party administration, medical claims processing and adjudication service.

Going forward, the strategy is to further develop MHC”s client portfolio and regional presence, invest further in technology and strengthen its position as the preferred corporate health benefits solution provider. The growth of the Company will also be supported by EQT”s Industrial Network and a board of directors with significant relevant experience and network.

Dr. Low Lee Yong, CEO of MHC Asia, said: ‘We were courted by different institutional investors, but we picked EQT to be our strategic investor and partner because we were very impressed by the EQT team. We share the same vision and passion about making a difference to transform and simplify healthcare with technology. What an exciting way to celebrate our 25th anniversary by having a trusted and friendly partner to support our growth and regional expansion!’

Eric Koh, COO of MHC Asia, said: ‘We want to delight our customers and give them insights that will enable them to make the optimal decisions. EQT gives us the ability to do more, do better and do smarter.’

Brian Chang, Partner at EQT Partners and Investment Advisor to the EQT Mid Market Asia III Fund, concluded: ‘EQT is impressed with MHC”s leading position and its innovative, technology-driven approach to go beyond the traditional role of a typical healthcare benefits administrator. EQT is fully committed to supporting MHC”s dynamic management team to continue delivering consistent growth through its various expansion strategies.’

Contact
Brian Chang, Partner at EQT Partners, Investment Advisor to the EQT Mid Market Asia III Fund, +65 6595 1830
EQT Press Office, press@eqtpartners.com, +46 8 506 55 334

About EQT

EQT is a leading investment firm with more than EUR 61 billion in raised capital across 29 funds and around EUR 40 billion in assets under management. EQT funds have portfolio companies in Europe, Asia and the US with total sales of more than EUR 19 billion and approximately 110,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership.

More info: www.eqtpartners.com

About MHC

MHC is a leading healthcare benefits administrator in Southeast Asia. Founded in 1994 and headquartered in Singapore, the Company serves several insurer and corporate clients and has approximately 800,000 corporate employees as members.

More info: www.mhcasia.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/eqt-ab/r/eqt-invests-in-mhc-asia–a-leading-healthcare-benefits-administrator-in-southeast-asia,c2777181

The following files are available for download:

https://mb.cision.com/Main/87/2777181/1017526.pdf

Press release EQT Mid Market Asia III MHC 190401

 

STOCKHOLM, April 1, 2019 /PRNewswire/ —

[[[tasteofexc

Read Full Article

The study examined past 30-day smoking abstinence rates three months after initial JUUL product purchase among a sample of 15,456 adult smokers aged 21+ years.  Abstinence was defined as zero puffs of a combustible cigarette in the past 30 days.  Results showed that 47.1 % of the 9,272 survey participants who completed the 3-month follow-up assessment had completely abstained from smoking for the prior 30 days.  Overall, 28.3% of all 15,456 participants who began the study abstained from smoking during the reporting period.

Importantly, the study also found that participants who had exclusively used non-tobacco flavors Mango, Cucumber, Fruit, Creme, Menthol, and Mint were 30% more likely to have abstained from smoking at three months compared to those who exclusively used tobacco flavors.  In addition to being the most commonly used flavors, smokers who primarily used Mint or Mango JUULpods in the 30 days prior to the 3-month assessment were 37% and 26% more likely, respectively, to have not smoked any cigarettes in the previous 30 days compared to primary users of Virginia Tobacco flavored JUULpods.

In total, the study identified eight variables that were significant in predicting the likelihood of past 30-day smoking abstinence after using JUUL products for three months, including frequency of JUUL use, smoking heaviness and duration, place of purchase, and purchase with intent to stop smoking completely.  Future analyses will include data from the same participants at 6 and 12-month follow-up assessments after initiating use of JUUL products.

‘The results of this study indicate that close to half of adult smokers who used a JUUL product for three months had abstained from smoking for the past 30 days, with even higher rates of abstinence observed among those who primarily used JUULpods in non-tobacco flavors,’ said Dr. Neil McKeganey, Director of the Centre for Substance Use Research (Glasgow, UK).  ‘Although additional follow-up research is needed, flavored JUULpods have been shown to have a significant impact in getting smokers to switch and ultimately abstain from cigarettes over a period of time.  We will continue to track this and other variables impacting smokers” likelihood of abstaining from cigarette use, including collecting additional survey data at both the 6 and 12-months mark after initiating JUUL use.’

‘Our mission is to improve the lives of the world”s one billion smokers by eliminating cigarettes and we are encouraged by these study findings that approximately half of smokers switch away from combustible cigarettes after three months of JUUL use,’ said Erik Augustson, Ph.D., MPH Senior Director of Behavioral Research at JUUL Labs. ‘We are committed to continuing to research the potential public health impact of our products and have over 100,000 participants enrolled in behavioral studies across the world, where we are collecting data on a range of topics, including factors that improve the likelihood of completely switching from combustible cigarettes and the role responsible flavors may play in that process.’

About the Study:

JUUL Labs commissioned and funded the Centre for Substance Use Research (CSUR) to independently design and administer the survey, and analyze and report the study results. Individuals were invited to participate in this study through email invitations to e-commerce customers and through inserts in JUUL starter kits distributed in retail stores across the U.S.  Eligible individuals were U.S. adults aged 21 years and older who had smoked at least 100 cigarettes in their lifetime, and had purchased their first JUUL starter kit from a U.S. retail store or through JUUL”s e-commerce store at www.juul.com within the past seven days.

About JUUL Labs, Inc.

JUUL Labs is committed to improving the lives of the world”s one billion adult smokers by eliminating cigarettes, the leading cause of preventable death in the world.  JUUL Labs” products are designed to help smokers switch.

JUUL Labs is equally committed to combating underage use of nicotine and tobacco products. The company launched a comprehensive action plan to address youth access, appeal, and use that includes restricting the sale of certain flavored JUULpods from traditional retail, enhancing our online age-verification, improving retailer compliance, eliminating use of Facebook and Instagram accounts and utilizing technology-based solutions to prevent youth use. We also actively support Tobacco 21 legislation to raise the minimum-purchasing age for all tobacco products, including vapor products, to 21. For more information on our mission and youth prevention initiatives, please visit https://newsroom.juul.com/.

Media Contacts
Press@juul.com

Photo – https://mma.prnewswire.com/media/844128/juul1.jpg  
Photo – https://mma.prnewswire.com/media/844129/juul.jpg

SAN FRANCISCO, April 1, 2019 /PRNewswire/ — The Harm Reduction Journal recently published results of a behavioral study examining the role of JUUL use, JUULpod flavors, and other factors in predicting past 30-day abstinence from cigarette smoking among new users of JUUL products.

[[[tasteofexc[[[tasteofexc

Read Full Article

Don”t miss out on business opportunities in Latin America Pharmaceutical Excipients Market

Growth in this market is driven by the growing pharmaceutical industry in Latin American countries such as Brazil, Mexico, and Argentina; increasing focus of MNCs on investing in the pharmaceutical and healthcare sectors in Latin America; growing pricing pressures; rapid growth in aging population & the subsequent increase in the prevalence of related diseases; and the availability of local and government funding for R&D activities. 

Download PDF Brochure:

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=41302221

Browse in-depth TOC on ‘Latin America Pharmaceutical Excipients Market

28 – Tables
11 – Figures   
281 – Pages  

By functionality, the filler & diluents segment accounted for the largest share of the Latin America Pharmaceutical Excipients Market

The Latin America Pharmaceutical Excipients Market, by functionality, is segmented into fillers & diluents, binders, suspending & viscosity agents, flavoring agents & sweeteners, coating agents, colorants, disintegrants, lubricants & glidants, preservatives, emulsifiers & solubilizers, and other functionalities. The fillers & diluents segment accounted for the largest market share in 2018. The increased use of fillers & diluents in the development and production of solid dosage form and the wide applications of diluents in the wet granulation and direct compression process for tablet formulation are driving the growth of the fillers & diluents segment.

Request Sample Pages: 

https://www.marketsandmarkets.com/requestsampleNew.asp?id=41302221

Mexico to dominate the Latin America Pharmaceutical Excipients Market during the forecast period

In 2018, Mexico dominated the Latin America Pharmaceutical Excipients Market, followed by Argentina. Over the past few years, Mexico has become an attractive destination for investment in the pharmaceutical industry due to its large pharmaceutical production and consumption capacity and the improved regulatory framework. Growing pharmaceutical production and consumption, increasing investments by MNCs, and improved regulatory framework are the major factors driving the growth of the pharmaceutical excipients market in Mexico.

Prominent players in the Latin America Pharmaceutical Excipients Market are DowDuPont (US), Roquette (France), Ashland (US), BASF (Germany), and Kerry Group (Ireland).

Inquiry Before Buying: 

https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=41302221

Browse Adjacent Markets @ Pharmaceuticals Market Research Reports & Consulting

About MarketsandMarkets™ 

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies” revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the ‘Growth Engagement Model – GEM’. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write ‘Attack, avoid and defend’ strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets”s flagship competitive intelligence and market research platform, ‘Knowledge Store’ connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/latin-america-pharmaceutical-excipient-market.asp

Visit Our Website: https://www.marketsandmarkets.com

https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg

CHICAGO, March 12, 2019 /PRNewswire/ — According to the new market research report Latin America Pharmaceutical Excipients Market by Functionality (Fillers, Coating, Disintegrants, Binders, Lubricants, Preservatives, Emulsifying Agents, Lubricants, Glidants, Diluents), Country (Mexico, Argentina, Columbia, Peru) – Forecast to 2024′, published by MarketsandMarkets™, the Latin America Pharmaceutical Excipients Market is projected to reach USD 579 million by 2024 from USD 403 million in 2019, at a CAGR of 7.5%.

[[[tasteofexc

Read Full Article

VALLEY COTTAGE, New York, Feb. 21, 2019 /PRNewswire/ — Sales of smart pill boxes and bottles are likely to reach around 800 thousand in 2019. According to a new analytical research study by Future Market Insights (FMI), smart pill boxes and bottles market will remain a high growth-low volume landscape over the course of next few years. Over 43% of total sales will be accounted by smart pill boxes. The report envisages a higher rate of adoption for smart pill bottles.

Almost 70% of adult patients are observed to discontinue or manipulate drug therapy, resulting in non-adherence to prescribed medication. The study opines that this directly adds to the economic burden on healthcare delivery system in form of emergency cases and hospitalization.

Smart pill boxes and bottles are increasingly being perceived as a potential solution to such challenges posed by increased healthcare delivery costs. Significance of medication adherence continues to rise with increasing prevalence of chronic conditions, propelling demand for smart pill boxes and bottles.

Request a Sample Report with Table of Contents and Figureshttps://www.futuremarketinsights.com/reports/sample/rep-gb-1710

Dementia and geriatric care remain the key application areas of smart pill boxes and bottles, according to the report. More than 80% of sales is accounted by aging patients and dementia-afflicted population. Cancer management is likely to emerge lucrative in terms of applicability in coming years.

With surging demand for high-quality healthcare delivery, senior care centers, hospitals, long-term care centers, and homecare settings are accelerating adoption of medication dispensers, thereby elevating the revenue growth of smart pill boxes and bottles market. Some of the leading companies are actively involved in the development of advanced technology medication dispensing devices with zero error risks during medication.

Buy this report @ https://www.futuremarketinsights.com/checkout/1710

Home care settings maintain the highest consumption share in smart pill boxes and bottles market that roughly equates 65% of total sales. Almost a fifth of smart pill boxes and bottles sold are installed at seniors care and assisted living centers. FMI”s analysis indicates that long-term care centers are also creating promising market opportunities for smart pill boxes and bottles manufacturers and distributors.

North America continues to reign supreme owing to early adoption of advanced technology enabled smart pill boxes and bottles, accounting for more than a third of the global market revenue. European market for smart pill boxes and bottles also represents a substantial volume share, majorly driven by German patients. South and East Asian regions are briskly developing high-potential markets for manufacturers and distributors of smart pill boxes and bottles, says the report.

Preview Analysis of Smart Pill Boxes & Bottles Market is segmented by (Type – Smart Pill Box & Smart Pill Bottles; Indication – dementia, Parkinson”s disease, cancer management, diabetes care, geriatric care, disability & others; Distribution channel – seniors care & assisted living, long term care centers & home care;) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018-2028: https://www.futuremarketinsights.com/reports/smart-pill-boxes-bottles-market

The vendor landscape of smart pill boxes and bottles market remains fairly consolidated and competitive, as Tier 1 manufacturers continue to account for a majority of share in the market in terms of volume. While dominance of Koninklijke Philips N.V., PharmRight Corporation & Livi, and AdhereTech prevails in smart pill boxes and bottles market, the report finds that the competition among these players is characterized by product innovation, new launches, and technological advancements.

FMI has tracked market performance for a decade-old projection period – 2018-2028. For exclusive insights on the various other aspects of smart pill boxes and bottles market landscape, write to the analyst at press@futuremarketinsights.com

Our advisory services are aimed at helping you with specific, customized insights that are relevant to your specific challenges. Let us know about your challenges and our trusted advisors will connect with youhttps://www.futuremarketinsights.com/ask-the-analyst/rep-gb-1710

More from Healthcare, Pharmaceuticals and Medical devices Market Insights Market Intelligence:

About Us

Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights and an aerial view of the competitive framework and future market trends.

Browse More Healthcare, Pharmaceuticals and Medical devices Market Insights

Contact Us
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
T (UK): + 44(0)20-7692-8790
Sales: sales@futuremarketinsights.com 
Press Office: Press@futuremarketinsights.com 
Blog: Market Research Blog 
Website: https:www.futuremarketinsights.com

Over 6 in 10 Smart Pill Boxes & Bottles Sell in Home Care Settings, Dementia & Geriatric Care Spur Demand Growth

[[[tasteofexc

Read Full Article